Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-319 intravenous infusion study in adults with systemic lupus erythematosus or Sjogren's disease
NL-OMON59026Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ABBV-319 in systemic lupus erythematosus (SLE) and Sjögren's syndrome, sponsored by AbbVie Inc. Started Nov 2025; status: recruiting.
02
Drugs
ABBV-319
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59026.